Contineum Therapeutics, Inc.
CTNMNasdaq
$14.23
↑ +1.6%Jul 17 close · end-of-day
Price
1Y↑ +271.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$531.3M
Enterprise Value
$285.0M
P/E
—
P/S
—
P/B
2.1
EV/EBITDA
—
PEG
—
FCF Yield
-10.8%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$58.4M
Free Cash Flow (TTM)
-$57.7M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-23.4%
ROIC
-1422.4%
Debt / Equity
—
Net Cash
$246.3M
Return 1Y
+270.6%
Company profile
We are a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications with high unmet need. Our principal executive offices are located at 10578 Science Center Drive, Suite 200, San Diego, California.
- CEO
- Carmine Stengone
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- www.contineum-tx.com
Management & directors
- Lorrain Daniel S.Chief Scientific Officer
- Stengone Carmine N.CEO and President
- Watkins TimCMO & Head of Development
Roles derived from SEC Form 4 filings.
Earnings
CTNM Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.39↓ -37.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $50.0M | $0.00 | — |
| Gross profit | — | — | — |
| Operating income | $16.1M | -$50.9M | -$68.1M |
| Net income | $22.7M | -$42.3M | -$60.0M |
| Diluted EPS | $0.08 | -$2.18 | -$2.17 |
| Operating cash flow | $19.3M | -$32.8M | -$55.3M |
| Free cash flow | $18.9M | -$33.4M | -$55.5M |
| Gross margin | — | — | — |
| Operating margin | 32.2% | — | — |
| Net margin | 45.4% | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$10.9M | -$13.0M | -$17.0M | -$18.1M | -$17.9M | -$14.9M | -$17.1M | -$16.9M |
| Net income | -$9.0M | -$10.3M | -$14.6M | -$16.0M | -$16.0M | -$12.8M | -$15.2M | -$14.5M |
| Diluted EPS | -$0.39 | -$0.40 | — | -$0.62 | — | — | — | -$0.39 |
| Operating cash flow | -$8.5M | -$6.2M | -$10.2M | -$14.4M | -$15.7M | -$12.2M | -$13.0M | -$16.3M |
| Free cash flow | -$8.6M | -$6.3M | -$10.4M | -$14.5M | -$15.7M | -$12.3M | -$13.1M | -$16.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-09 | Lorrain Daniel S.· Chief Scientific Officer | Sale | 25 | $16.00 | $400.00 | filing |
| 2026-07-09 | Lorrain Daniel S.· Chief Scientific Officer | Option exercise | 25 | $1.01 | $25.25 | filing |
| 2026-07-08 | Stengone Carmine N.· CEO and President | Sale | 2,500 | $16.00 | $40,000.00 | filing |
| 2026-07-08 | Lorrain Daniel S.· Chief Scientific Officer | Sale | 1,015 | $16.00 | $16,240.00 | filing |
| 2026-07-08 | Stengone Carmine N.· CEO and President | Option exercise | 2,500 | $1.01 | $2,525.00 | filing |
| 2026-07-08 | Lorrain Daniel S.· Chief Scientific Officer | Option exercise | 1,015 | $1.01 | $1,025.15 | filing |
| 2026-07-01 | Lorrain Daniel S.· Chief Scientific Officer | Sale | 5,852 | $15.67 | $91,681.53 | filing |
| 2026-07-01 | Lorrain Daniel S.· Chief Scientific Officer | Sale | 2,501 | $16.24 | $40,608.49 | filing |
| 2026-07-01 | Lorrain Daniel S.· Chief Scientific Officer | Option exercise | 4,183 | $1.01 | $4,224.83 | filing |
| 2026-06-30 | Lorrain Daniel S.· Chief Scientific Officer | Sale | 28,826 | $16.04 | $462,288.33 | filing |
| 2026-06-30 | Watkins Tim· CMO & Head of Development | Sale | 10,833 | $16.02 | $173,590.16 | filing |
| 2026-06-30 | Stengone Carmine N.· CEO and President | Sale | 10,000 | $16.01 | $160,080.00 | filing |
| 2026-06-30 | Watkins Tim· CMO & Head of Development | Option exercise | 10,833 | $4.50 | $48,748.50 | filing |
| 2026-06-30 | Lorrain Daniel S.· Chief Scientific Officer | Option exercise | 28,826 | $1.01 | $29,114.26 | filing |
| 2026-06-30 | Stengone Carmine N.· CEO and President | Option exercise | 7,500 | $1.01 | $7,575.00 | filing |
| 2026-06-30 | Stengone Carmine N.· CEO and President | Option exercise | 2,500 | $1.26 | $3,150.00 | filing |
| 2026-06-01 | Lorrain Daniel S.· Chief Scientific Officer | Sale | 4,170 | $13.16 | $54,862.19 | filing |
| 2026-05-01 | Lorrain Daniel S.· Chief Scientific Officer | Sale | 3,870 | $13.06 | $50,542.20 | filing |
| 2026-05-01 | Lorrain Daniel S.· Chief Scientific Officer | Sale | 300 | $13.84 | $4,152.00 | filing |
| 2026-04-06 | Lorrain Daniel S.· Chief Scientific Officer | Sale | 4,170 | $13.43 | $56,013.94 | filing |
| 2026-03-02 | Lorrain Daniel S.· Chief Scientific Officer | Sale | 4,170 | $15.01 | $62,585.03 | filing |
| 2026-03-02 | Watkins Tim· CMO & Head of Development | Sale | 3,611 | $15.02 | $54,220.25 | filing |
| 2026-03-02 | Watkins Tim· CMO & Head of Development | Option exercise | 3,611 | $4.50 | $16,249.50 | filing |
| 2026-02-25 | Lorrain Daniel S.· Chief Scientific Officer | Sale | 3,824 | $16.01 | $61,227.98 | filing |
| 2026-02-25 | Stengone Carmine N.· CEO and President | Sale | 2,700 | $16.02 | $43,241.85 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.